Litigation Details for ORTHO-MCNEIL PHARM v. BARR LABORATORIES (D.N.J. 2003)

ORTHO-MCNEIL PHARM v. BARR LABORATORIES (D.N.J. 2003)

Docket		Date Filed	2003-10-01
Court	District Court, D. New Jersey	Date Terminated	2009-07-29
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand		Referred To	Michael Andre Shipp
Parties	BARR LABORATORIES
Patents	6,214,815
Link to Docket	External link to docket

Details for ORTHO-MCNEIL PHARM v. BARR LABORATORIES (D.N.J. 2003)

Date Filed	Document No.	Description	Snippet	Link To Document
2003-10-01				External link to document

Ortho-McNeil Pharmaceutical v. Barr Laboratories, 2:03-cv-04678: Litigation Summary and Patent Analysis

Last updated: August 4, 2026

Ortho-McNeil Pharmaceutical, Inc. v. Barr Laboratories, Inc., No. 2:03-cv-04678, was an ANDA patent dispute in the U.S. District Court for the District of New Jersey involving Ortho-McNeil's topiramate product, Topamax. The case arose from Barr's Paragraph IV challenge to patents listed for topiramate tablets. The dispute formed part of broader generic Topamax litigation involving multiple ANDA filers.

What drug and patents were involved in Ortho-McNeil v. Barr?

The litigation concerned Topamax, whose active ingredient is topiramate. Topiramate is an anticonvulsant approved for epilepsy and migraine prevention. Ortho-McNeil, a Johnson & Johnson company, marketed Topamax in the United States.

The asserted patent estate included patents directed to topiramate compositions and therapeutic uses. The principal patent family associated with the Topamax generic disputes included:

Patent	General subject matter	Relevance
U.S. Patent No. 4,513,006	Topiramate compound	Early compound protection; expired before the core Barr litigation
U.S. Patent No. 5,387,700	Topiramate pharmaceutical compositions	Core composition patent in generic challenges
U.S. Patent No. 5,753,693	Topiramate treatment methods	Method-of-use protection
U.S. Patent No. 6,274,740	Migraine-treatment methods involving topiramate	Later method-of-use protection

The exact claims litigated depend on the ANDA and asserted count in the docket. The case should therefore be analyzed as part of the broader Topamax patent dispute rather than as an isolated infringement decision.

When did Ortho-McNeil file the case against Barr?

Ortho-McNeil filed the action in 2003 after Barr notified the patent holder that it had submitted an ANDA containing a Paragraph IV certification. The filing triggered the Hatch-Waxman statutory stay, which generally prevents FDA approval of the challenged ANDA for 30 months unless the case is resolved earlier or the court orders otherwise. [1]

Barr's Paragraph IV certification alleged that the relevant Topamax patents were invalid, unenforceable, or not infringed. The litigation followed the standard Hatch-Waxman sequence:

1. Barr submitted an ANDA for generic topiramate.
2. Barr sent a Paragraph IV notice to Ortho-McNeil.
3. Ortho-McNeil filed a patent-infringement complaint.
4. FDA approval was subject to the statutory litigation stay.
5. The patent disputes proceeded alongside related cases against other generic applicants.

What was the legal issue in the Topamax patent litigation?

The main legal issues were patent validity, infringement, and enforceability.

Patent validity

The generic defendants challenged the asserted patents on grounds including obviousness and lack of adequate patentable subject matter. The analysis focused on whether the claimed topiramate formulation or therapeutic use would have been obvious to a person of ordinary skill in the art based on earlier anticonvulsant compounds, formulation techniques, and clinical knowledge.

Patent infringement

Ortho-McNeil argued that Barr's proposed generic product would fall within the asserted composition claims. For method-of-use claims, the analysis required examination of the FDA-approved labeling and the uses encouraged by the proposed ANDA product.

Under 35 U.S.C. § 271(e)(2), filing an ANDA with a Paragraph IV certification is treated as an artificial act of infringement for purposes of resolving the patent dispute before commercial launch. [2]

Patent enforceability

The Topamax-related litigation also generated allegations concerning inequitable conduct and the disclosure of material information to the U.S. Patent and Trademark Office. Those issues were significant because a finding of inequitable conduct could render an otherwise valid patent unenforceable.

What was the litigation outcome in Ortho-McNeil v. Barr?

The Barr docket is part of a group of Topamax-related actions that did not produce a single, universally controlling judgment applicable to every generic applicant. Outcomes differed by defendant, patent, claim, and settlement or procedural posture.

The most commercially important result of the broader litigation was that generic topiramate eventually entered the U.S. market before the full nominal expiration of every Topamax-related patent. Generic entry followed a combination of patent challenges, court decisions, and agreements involving generic manufacturers.

The record is best understood as follows:

Issue	Practical result
Original topiramate compound patent	No longer blocked generic entry by the time of the later ANDA litigation
Composition patents	Subject to Paragraph IV validity and infringement challenges
Method-of-use patents	Relevant to epilepsy and migraine indications, with narrower enforcement scope
30-month stay	Applied when statutory requirements were met
Commercial generic entry	Occurred after the broader patent disputes and regulatory barriers were resolved
Barr-specific disposition	Must be read from the docket's final judgment, dismissal, or settlement entry rather than inferred from another defendant's case

What was the FDA and Orange Book status of Topamax?

Topamax was approved by FDA as an immediate-release topiramate product. FDA's Orange Book listed patent information submitted by the brand sponsor, including patents covering the drug substance, formulations, or approved methods of use.

Orange Book listing affects the Hatch-Waxman pathway in three ways:

• It identifies patents that an ANDA applicant must address.
• It determines whether a Paragraph IV notice may trigger litigation.
• It can create a 30-month approval stay when the patent holder files suit within the statutory period.

Orange Book listing does not independently establish patent validity or infringement. A listed patent remains vulnerable to invalidity, unenforceability, noninfringement, or delisting arguments.

The regulatory distinction between product claims and method-of-use claims was important for Topamax. A generic applicant could seek approval for fewer indications through a section viii statement and a carved-out label. That approach can reduce exposure to method-of-use claims but does not avoid composition or drug-substance patents.

How strong was Ortho-McNeil's patent estate?

The Topamax estate had mixed strength.

Stronger protection

The original compound patent provided the most valuable exclusivity because it covered topiramate itself. Once that patent expired, the estate depended on narrower composition and method-of-use claims.

Weaker protection

Method-of-use patents generally provide narrower protection than compound patents. They can be avoided through labeling strategies, indication carve-outs, or proof that the generic applicant does not actively encourage the patented use.

Formulation and composition patents can delay generic entry when they cover the marketed dosage form and cannot be avoided through a simple label carve-out. Their strength depends on claim scope, prior art, written-description support, and the actual composition disclosed in the ANDA.

Commercial assessment

The estate was commercially meaningful but vulnerable to Paragraph IV attacks. Topiramate was a small-molecule product, so biosimilar law was irrelevant. Once the key composition and method-of-use barriers were removed or bypassed, generic competition could enter without the development and interchangeability issues associated with biologics.

Which companies challenged Topamax patents?

Topamax faced challenges from multiple generic manufacturers, including Barr Laboratories and Mylan. Other applicants also pursued topiramate ANDAs or participated in related patent actions. The generic landscape mattered because the first successful Paragraph IV filer could obtain 180 days of generic exclusivity under the pre-2003 Hatch-Waxman framework, subject to the statutory rules then in effect.

The commercial effect was material. Topiramate had established use in epilepsy and migraine prevention, and generic substitution could rapidly reduce branded revenue after launch.

Did biosimilar risk affect this litigation?

No. Topiramate is a synthetic small-molecule drug, not a biologic. The relevant competitive threat was generic substitution under the ANDA pathway, not biosimilar approval under the Public Health Service Act.

The key barriers were:

• Orange Book patents;
• Paragraph IV certification;
• the 30-month stay;
• ANDA litigation;
• manufacturing equivalence and bioequivalence;
• labeling restrictions; and
• launch timing after patent resolution.

What generic launch scenarios existed for Barr?

Barr had three principal launch pathways.

Launch after prevailing in litigation

If Barr defeated the asserted patents on invalidity, unenforceability, or noninfringement grounds, FDA could approve the ANDA without waiting for patent expiration, subject to any applicable appeal-related stay.

Launch after settlement

A settlement could establish a negotiated entry date before the latest patent expiration. The economic terms would determine whether the agreement created antitrust risk under the Federal Trade Commission's pay-for-delay framework.

Launch after patent expiration or carve-out

Barr could wait for patent expiration or seek approval with a section viii statement excluding a patented method of use. That option could preserve regulatory approval for noninfringing indications while avoiding direct infringement of a use patent.

Did the case produce a major Federal Circuit precedent?

The most cited Topamax-related appellate authority is Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc., 520 F.3d 1358 (Fed. Cir. 2008). That decision addressed the patentability and interpretation of claims involving topiramate treatment and is distinct from the Barr docket. It should not be treated as the final judgment in No. 2:03-cv-04678. [3]

The distinction matters for diligence. A Federal Circuit opinion involving Mylan may clarify the legal framework for the Topamax patent estate while leaving the Barr-specific disposition controlled by the District of New Jersey docket.

What patent litigation affects Topamax generic entry?

Topamax generic entry was affected by the cumulative patent position rather than one case alone. The relevant assessment includes:

Risk category	Assessment
Compound patent risk	Low after expiration
Formulation patent risk	Dependent on the specific ANDA formulation
Method-of-use risk	Potentially manageable through label carving
Litigation risk	High during the active 30-month stay
Biosimilar risk	None
Manufacturing risk	Moderate; generic topiramate requires compliant synthetic manufacture and bioequivalence
Settlement risk	Dependent on entry date and any compensation provisions
Revenue risk to brand	High after multiple generic approvals

Key Takeaways

• Ortho-McNeil v. Barr, No. 2:03-cv-04678, was a Hatch-Waxman dispute over generic topiramate and the Topamax patent estate.
• Barr's Paragraph IV certification challenged Ortho-McNeil's Orange Book-listed patents.
• The dispute involved composition and method-of-use protection rather than biosimilar regulation.
• The original compound patent was no longer the principal barrier during the later generic litigation.
• Generic entry depended on the validity, enforceability, and scope of narrower formulation and use patents.
• Broader Topamax litigation included cases against Mylan and other ANDA applicants; those decisions should not be substituted for the Barr docket's final disposition.
• The commercial risk to Topamax increased materially once generic manufacturers overcame or bypassed the remaining patent claims.

FAQs

What was the drug in Ortho-McNeil Pharmaceutical v. Barr Laboratories?

The case involved topiramate, marketed by Ortho-McNeil as Topamax for epilepsy and migraine prevention.

Was Ortho-McNeil v. Barr a Paragraph IV case?

Yes. The action arose from Barr's ANDA and Paragraph IV challenge to patents associated with generic topiramate.

Did the case involve a biologic or biosimilar?

No. Topiramate is a small-molecule drug regulated through the ANDA generic pathway.

Can a generic manufacturer avoid a Topamax method-of-use patent?

Potentially. A generic applicant may use a section viii statement and omit a patented indication if the remaining label and marketing conduct do not encourage infringement.

Why should the Barr docket be distinguished from the Mylan Topamax cases?

The cases involved related products and patent issues but different defendants, pleadings, evidence, and procedural histories. The final disposition in the Barr case must be determined from docket 2:03-cv-04678 itself.

References

1. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. FDA.

2. 35 U.S.C. § 271(e)(2) (2024).

3. Ortho-McNeil Pharmaceutical, Inc. v. Mylan Laboratories, Inc., 520 F.3d 1358 (Fed. Cir. 2008).

4. U.S. Patent and Trademark Office. (n.d.). Patent Center: Ortho-McNeil Pharmaceutical patent records. USPTO.

5. U.S. District Court for the District of New Jersey. (2003). Ortho-McNeil Pharmaceutical, Inc. v. Barr Laboratories, Inc., No. 2:03-cv-04678, docket record.